Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2014

Summary of Significant Accounting Policies [Abstract]

Finite-lived intangible assets roll-forward [Text Block]

The following table summarizes the activity related to the finite-lived intangible asset:

	Finite-lived intangible assets
Balance at January 1, 2013	$	-
Reclassification from indefinite lived IPR&D		21
Amortization expense		(2	)
Balance at December 31, 2013		19
Amortization expense		(3	)
Impairment		(16	)
Balance at December 31, 2014	$	-

Components of finite lived intangible assets [Text Block]

The following table reflects, prior to the third quarter write-off, the components of the finite lived intangible assets as of December 31, 2013:

	Gross Amount		Accumulated Amortization		Net Carrying Value
Finite lived intangible assets	$	21	$	2	$	19
Total	$	21	$	2	$	19

The weighted-average remaining life of the finite lived intangible assets was approximately five years at December 31, 2013.

PROGENICS PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - continued

(amounts in thousands, except per share amounts or as otherwise noted)

The following table summarizes the activity related to the Company's goodwill and indefinite lived IPR&D:

	Goodwill		IPR&D
Balance at January 1, 2013	$	-	$	-
Increase related to MIP acquisition		7,702		32,300
Reclassification to finite lived IPR&D		-		(21	)
Impairment		-		(919	)
Balance at December 31, 2013	$	7,702	$	31,360
Impairment		-		(2,660	)
Balance at December 31, 2014	$	7,702	$	28,700

Schedule of estimated useful lives of fixed assets

Expenditures for maintenance and repairs which do not materially extend the useful lives of the assets are charged to expense as incurred. The cost and accumulated depreciation of assets retired or sold are removed from the respective accounts and any gain or loss is recognized in operations. The estimated useful lives of fixed assets are as follows:

Computer equipment	3 years
Machinery and equipment	5-7 years
Furniture and fixtures	5 years
Leasehold improvements	Earlier of life of improvement or lease

Deferred leases

PROGENICS PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - continued

(amounts in thousands, except per share amounts or as otherwise noted)

Deferred Lease Liability and Incentive

Our lease agreements include fixed escalations of minimum annual lease payments and we recognize rental expense on a straight-line basis over the lease terms and record the difference between rent expense and current rental payments as deferred lease liability. Deferred lease incentive includes a construction allowance from our landlord which is amortized as a reduction to rental expense on a straight-line basis over the lease term. As of December 31, 2014 and 2013, the Consolidated Balance Sheets include the following:

	2014		2013
Other current liabilities:
Deferred lease incentive	$	115	$	115
Total other current liabilities	$	115	$	115
Other liabilities:
Deferred lease liability	$	336	$	224
Deferred lease incentive		575		690
Total other liabilities	$	911	$	914